



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45389

Title: Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in squamous cell lung cancer: a case report and review of the literature

Reviewer's code: 05078266

Reviewer's country: Japan

Science editor: Jin-Lei Wang

Date sent for review: 2019-01-04

Date reviewed: 2019-01-08

Review time: 19 Hours, 3 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

In this manuscript, authors describe significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in squamous cell lung cancer. This report may be of interest for clinicians; however, the manuscript contains some issues



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

that needs to be addressed prior to publication. 1. If authors used liquid biopsy for T790M, need to show the result in the manuscript. 2. Authors need to add sentence about no evidence of adenosquamous carcinoma or cancers with a mixture of other components, not only in the discussion but also in case presentation. 3. Authors described in the introduction “ We previously performed a multicentre retrospective study of EGFR-positive SCC patients treated with EGFR-TKI [5], which showed that the progression-free survival time (PFS) for SCC is only 5.1 months, significantly inferior to lung adenocarcinoma [6] “. → Authors need to show the PFS of adenocarcinoma, too, and described , “ indicating that EGFR signalling pathways in SCC may not be identical to that in adenocarcinoma. “ → Authors showed overall survival was 29 months, indicating EGFR signalling pathways may be identical in this case ? Authros need to clear this point in the discussion.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No